| DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. | None |
| Taken together, our results suggest that DLC-1 might be an NPC-related tumor suppressor gene affected by aberrant promoter methylation and gene deletion. | None |
| DLC1 appears to be a major tumor suppressor genes implicated in the pathogenesis of these tumors | None |
| Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. | None |
| These results provide a novel mechanism whereby the SH2 domain of cten-mediated focal adhesion localization of DLC-1 plays an essential role in its tumor suppression activity. | None |
| DLC-1:a Rho GTPase-activating protein and tumour suppressor. | None |
| Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA pathway that may be targeted therapeutically. | None |
| DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. | None |
| p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. | None |
| Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. | None |
| DLC-1 is a tumor suppressor protein with RhoGAP activity and roles in regulation of the cytoskeleton and cell motility [review] | None |
| Results confirm the role of DLC1 gene as a tumor suppressor, which may be manifested by regulation of p21 and cyclinDl. | None |
| Phosphorylation of DLC1 and DLC2 by protein kinase B at the conserved residue points to a common regulatory mechanism of the DLC tumor suppressor family. | None |
| MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. | None |
| The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. | None |
| A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. | None |
| identified a new isoform of DLC1 with tumor suppressive function. The differential expression of various DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during carcinogenesis | None |
| Results suggest that a novel GAP-independent mechanism contributes to the tumor suppressive activity of DLC1, and highlight the importance and complexity of protein-protein interactions involving DLC1 in certain cancers. | None |
| The tumor suppressor DLC1 utilizes a novel binding site for tensin2 PTB domain interaction | None |
| complex formation between the DLC1 START domain and CAV-1 contributes to DLC1 tumor suppression via a RhoGAP-independent mechanism, and suggest that DLC1 inactivation probably contributes to cancer progression. | None |